BiologicalDrug
Necitumumab clinical trials
Also written LY3012211, IMC-11F8 and Portrazza®.
- studies test it
- 20
- open now
- 0
- in phase 3
- 2
- first study started
- 2004
How studies write it
Studies that test it under each name
Brand
Studies by the year they started
20 studies that test it; most in 2015 (4)
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2007 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2012 | 2 |
| 2013 | 3 |
| 2015 | 4 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 10
- Phase 2
- 11
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 3
Eli Lilly and Company (16) · National Cancer Institute (NCI) (1) · Jonsson Comprehensive Cancer Center (1) · ImmunityBio, Inc. (1) · Vanderbilt-Ingram Cancer Center (1)
Often tested with
Tested in the same studies.
Gemcitabine (3) · Cisplatin (3) · Osimertinib (2) · Albumin-Bound Paclitaxel (2) · Paclitaxel (2) · Carboplatin (2) · Fluorouracil (2) · Trastuzumab (1)
Studies
Open first, then newest update. How each study uses necitumumab is read from its arms, and is right about nine times in ten.
Testing it · 20
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02496663Written as Necitumumab
- Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung CancerActive, not recruitingPhase 1/2Jonsson Comprehensive Cancer CenterNCT04285671Written as Necitumumab
- First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-CisplatinCompletedPhase 3Eli Lilly and CompanyNCT00981058Written as Necitumumab
- QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have ProgressedTerminatedPhase 1/2ImmunityBio, Inc.NCT03387111Written as Necitumumab
- A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung CancerCompletedPhase 1Eli Lilly and CompanyNCT02789345Written as Necitumumab
- Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung CancerTerminatedPhase 1Vanderbilt-Ingram Cancer CenterNCT03054038Written as Necitumumab
- First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-CisplatinCompletedPhase 3Eli Lilly and CompanyNCT00982111Written as Necitumumab
- A Study of LY3023414 and Necitumumab in Squamous Lung CancerTerminatedPhase 2Eli Lilly and CompanyNCT02443337Written as Necitumumab
- A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLCCompletedPhase 2Eli Lilly and CompanyNCT02392507Written as Necitumumab
- A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLCCompletedPhase 1Eli Lilly and CompanyNCT02451930Written as Necitumumab
- A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1Eli Lilly and CompanyNCT02411591Written as Necitumumab
- A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1/2Eli Lilly and CompanyNCT01763788Written as Necitumumab
- A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-CisplatinCompletedPhase 2Eli Lilly and CompanyNCT01606748Written as Necitumumab
- A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Naïve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)WithdrawnPhase 2Eli Lilly and CompanyNCT02941601Written as Necitumumab
- A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung CancerCompletedPhase 2Eli Lilly and CompanyNCT01769391Written as Necitumumab
- Study of IMC-11F8 in Participants With Advanced Solid TumorsCompletedPhase 1Eli Lilly and CompanyNCT01088464Written as IMC-11F8
- A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid TumorsCompletedPhase 2Eli Lilly and CompanyNCT01624467Written as Necitumumab
- A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung CancerCompletedPhase 2Eli Lilly and CompanyNCT01788566Written as Necitumumab
- Study of IMC-11F8 in Participants With Colorectal CancerCompletedPhase 2Eli Lilly and CompanyNCT00835185Written as IMC-11F8 (necitumumab)
- Study of IMC-11F8 in Patients With Tumors Who Have Not Responded to Standard TherapyCompletedPhase 1Eli Lilly and CompanyNCT00801177Written as IMC-11F8
Given in every arm · 1 — necitumumab is usual care beside what is tested
Codes
What other systems call necitumumab · ClinicalTrials.gg INT005254
- MeSH (NLM) C527969necitumumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 2BT4C47RUINECITUMUMABConfirmed FDA, NLM, Wikidata
- RxNorm 1723738One source FDA
- Wikidata Q6985503necitumumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88281NecitumumabOne source FDA
- DrugBank DB09559One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C527969 | necitumumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 2BT4C47RUI | NECITUMUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1723738 | — | One source FDA |
| Wikidata | Q6985503 | necitumumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88281 | Necitumumab | One source FDA |
| DrugBank | DB09559 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.